Search Result

Results for "

Triple+Negative

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) 5-HT Receptor (2) ACSL Family (3) Acyltransferase (1) ADC Antibody (7) Adenosine Receptor (1) Akt (17) AMPK (6) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (1) Annexin A (2) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (3) Apoptosis (141) Aryl Hydrocarbon Receptor (3) Atg4 (1) Atg7 (1) Atg8/LC3 (1) ATM/ATR (2) ATP-binding cassette (ABC) transporters (1) Aurora Kinase (9) Autophagy (27) Bacterial (1) Bcl-2 Family (19) Beclin1 (1) Biochemical Assay Reagents (4) c-Fms (1) c-Met/HGFR (2) c-Myc (7) C-type Lectin-like Receptors (CTLRs) (1) Cadherin (3) Calcium Channel (1) CaMK (4) Carbonic Anhydrase (2) Carboxypeptidase (1) Casein Kinase (2) Caspase (25) Cathepsin (2) CD3 (1) CD47 (1) CD73 (2) CDK (25) Choline Kinase (3) ClpP (1) COX (1) CXCR (1) Cytochrome P450 (3) Deubiquitinase (2) Discoidin Domain Receptor (1) DNA Methyltransferase (3) DNA/RNA Synthesis (21) Drug Derivative (6) Drug Intermediate (4) Drug Isomer (1) Dynamin (1) DYRK (1) E1/E2/E3 Enzyme (3) Early 2 Factor (E2F) (1) EGFR (8) Elastase (1) Endogenous Metabolite (4) Enolase (1) Epigenetic Reader Domain (10) ERK (11) Estrogen Receptor/ERR (1) Eukaryotic Initiation Factor (eIF) (3) Exosomes (1) FAK (8) Fat Mass and Obesity-associated Protein (FTO) (1) Ferroptosis (15) FGFR (5) Fluorescent Dye (5) Formyl Peptide Receptor (FPR) (1) Fungal (1) G-quadruplex (1) Galectin (1) GLUT (1) Glutaminase (2) Glutathione Peroxidase (9) GSK-3 (2) HDAC (14) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (3) Histone Methyltransferase (15) HIV (3) HIV Protease (1) HOXA (1) HSP (5) Hsp-targeting Chimeras (1) HyT (1) IAP (2) IFNAR (1) IGF-1R (2) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (2) Integrin (4) Interleukin Related (5) Isotope-Labeled Compounds (2) JAK (6) JNK (3) Kinesin (1) KLF (2) Ligands for E3 Ligase (1) Lipase (1) Liposome (1) Lipoxygenase (2) LPL Receptor (1) MAGL (1) MARK (1) MASTL (1) MDM-2/p53 (8) Melanocortin Receptor (1) Microtubule/Tubulin (8) Mitochondrial Metabolism (3) Mixed Lineage Kinase (1) MMP (6) MNK (1) Molecular Glues (4) Monoamine Oxidase (1) mTOR (11) NAMPT (2) Necroptosis (5) NF-κB (11) NO Synthase (2) Notch (1) Nuclear Hormone Receptor 4A/NR4A (2) Nucleoside Antimetabolite/Analog (1) p38 MAPK (5) p62 (1) PAI-1 (1) PAK (2) PANoptosis (2) Parasite (1) PARP (28) PD-1/PD-L1 (7) PDK-1 (1) PERK (2) Phosphatase (3) Photosensitizer (1) PI3K (7) Pim (1) PIN1 (2) Polo-like Kinase (PLK) (1) Potassium Channel (1) PPAR (2) Prolyl Endopeptidase (PREP) (1) PROTACs (26) Protease Activated Receptor (PAR) (1) Protein Arginine Deiminase (2) PSMA (1) Pyroptosis (3) Pyruvate Kinase (2) RAD51 (2) Radionuclide-Drug Conjugates (RDCs) (1) Raf (4) RAR/RXR (1) Ras (6) Reactive Oxygen Species (ROS) (25) Reference Standards (9) Ribosomal S6 Kinase (RSK) (1) RIBOTAC (1) RIP kinase (2) ROCK (3) ROR (2) SARS-CoV (2) Ser/Thr Kinase (2) Ser/Thr Protease (1) SHP2 (1) Sialyltransferase (3) Sigma Receptor (1) Sirtuin (2) Src (3) STAT (13) STING (2) Survivin (1) TAM Receptor (3) Telomerase (1) TGF-beta/Smad (5) TGF-β Receptor (3) TNF Receptor (3) Toll-like Receptor (TLR) (1) Topoisomerase (3) Transferrin Receptor (2) Transmembrane Glycoprotein (4) TREM receptor (1) TROP2 (5) TRP Channel (1) TrxR (1) ULK (6) VD/VDR (1) VEGFR (9) Wee1 (2) Wnt (3) YAP (2) β-catenin (3)
By Research Areas:	Cancer (364) Cardiovascular Disease (3) Endocrinology (1) Infection (10) Inflammation/Immunology (16) Metabolic Disease (8) Neurological Disease (12)
Click Chemistry:	DBCO (1) Alkynes (6)
Oligonucleotides:	Fluorescent Lipids (1) Adenosine (1) Pegylated Lipids (1) Nucleoside Analogs (1) Phospholipids (1)

365

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148761

Zadavotide guraxetan 2 Publications Verification PSMA I&T; PNT-2002	PSMA	Cancer
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .

HY-N0770

Isoliensinine 4 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells .

HY-136420

SJF-0628	PROTACs Raf Apoptosis	Inflammation/Immunology Cancer
SJF-0628 is a RAF PROTAC degrader. SJF-0628 induces targeted degradation of BRAF in various cancer cell lines (colorectal cancer cell lines (Colo-205, LS-411N, HT-29, RKO) and triple-negative breast cancer cell line DU-4475). SJF-0628 decreases pMEK and pErk levels in DU-4475 cells. SJF-0628 has anti-tumor activity. SJF-0628 can be used for research of colorectal cancer and triple-negative breast cancer. (Pink: RAF ligand (HY-12057), Blue: VHL Ligand ( HY-125845), Black: Linker (HY-B0912)) .

HY-155663

GPX4-IN-5 1 Publications Verification	Glutathione Peroxidase Ferroptosis	Cancer
GPX4-IN-5 is a covalent inhibitor of GPX4 (IC₅₀: 0.12 μM). GPX4-IN-5 can induce ferroptosis and has anti-tumor effects. GPX4-IN-5 can be used in the study of triple-negative breast cancer (TNBC) .

HY-162250

MS8847	PROTACs Histone Methyltransferase	Cancer
MS8847 is a PROTAC degrader and antiproliferative agent targeting EZH2 (DC₅₀=34.4 nM in EOL-1 MLL-rAML cells). MS8847 recruits the E3 ligase von Hippel-Lindau (VHL) to mediate the degradation of EZH2 via the ubiquitin-proteasome system. MS8847 induces antiproliferative effects in MLL-rearranged acute myeloid leukemia cells and inhibits the growth of triple-negative breast cancer cell lines or 3D triple-negative breast cancer models. MS8847 is applicable to research related to MLL-rearranged acute myeloid leukemia and triple-negative breast cancer .

HY-168162

ZLC491	PROTACs CDK	Cancer
ZLC491 is an orally active PROTAC degrader that selectively targets CDK12/CDK13 and exhibits certain oral bioavailability. ZLC491 induces cereblon- and proteasome-dependent selective degradation of CDK12 and CDK13. ZLC491 inhibits the transcription and expression of long genes, and mainly acts on a subset of DNA damage response genes. ZLC491 inhibits the proliferation of various triple-negative breast cancer cells. ZLC491 can be used in research related to triple-negative breast cancer .

HY-12246

XEN445 1 Publications Verification	Lipase	Cardiovascular Disease Metabolic Disease Cancer
XEN445 is a potent, selective and orally active endothelial lipase (EL) inhibitor with an IC₅₀ value of 0.237 μM. XEN445 selectively inhibits phospholipase enzymatic activity of LIPG. XEN445 raises plasma HDL and cholesterol levles. XEN445 induces G1 cell cycle arrest, reduces cell viability, suppresses cancer stem cell self-renewal, and inhibits tumor formation in LIPG-expressing triple-negative breast cancer cells, while showing no inhibitory effect on invasiveness or cancer stem cell stemness in these cells. XEN445 can be used for the research of cancer and metabolic disease, such as triple-negative breast cancer .

HY-P11051

GE11, Cys Conjugated	Biochemical Assay Reagents	Cancer
GE11, Cys Conjugated is a peptide conjugate. GE11, Cys Conjugated consists of GE11 (HY-P10128) conjugated to a GGGGC sequence. GE11, Cys Conjugated can be used to synthesize stimulus-responsive peptide nanomaterials (SRPNs) for photoacoustic imaging and cancer research, such as studies on triple-negative breast cancer (TNBC) .

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .

HY-168894

CT-1	Ferroptosis JAK STAT p38 MAPK AMPK GSK-3 Apoptosis HSP TNF Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment .

HY-Y0519

Pyrimidine	Endogenous Metabolite	Neurological Disease Cancer
Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research .

HY-148334

MS8815	PROTACs Histone Methyltransferase	Cancer
MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. MS8815 has inhibition activity for EZH2 with an IC₅₀ value of 8.6 nM. MS8815 can be used for the research of triple-negative breast cancer (TNBC) .

HY-114979

Pyoluteorin	Antibiotic Fungal Apoptosis	Infection Cancer
Pyoluteorin is an antibiotic that inhibits Oomycete fungi, including the plant pathogen Pythium ultimum, and suppresses plant diseases caused by this fungus . Pyoluteorin induces human triple-negative breast cancer MDA-MB-231 cells apoptosis in vitro. Pyoluteorin can be used for the research of human triple-negative breast cancer .

HY-22445

MY05	c-Myc	Cancer
MY05 selectively targets c-MYC in cells and disrupts MYC-MAX interaction. MY05 engages intracellular c-MYC, modulates c-MYC thermal stability, reduces c-MYC transcriptional targets, and possesses anticancer activity (TNBC, Triple-Negative Breast Cancer) .

HY-W441002

DSPE-succinic acid	Drug Derivative Drug Intermediate	Cancer
DSPE-succinic acid is a derivative of Succinic acid (HY-N0420) and an intermediate of DSPE-Doxorubicin. DSPE-succinic acid can be used to synthesize DSPE-Doxorubicin via EDC/NHS activation. DSPE-succinic acid is applicable to the research of triple-negative breast cancer .

HY-W008581

Estradiol 3-methyl ether 3-O-Methyl estradiol; 17β-Estradiol 3-methyl ether; 3-Methoxyestradiol	Biochemical Assay Reagents TRP Channel Microtubule/Tubulin Autophagy	Metabolic Disease Cancer
Estradiol 3-methyl ether (EDME) is a highly selective TRPML1 ion channel antagonist and microtubule (microtubule) depolymerizing agent, with IC₅₀ values of 0.22 μM and 3.8 μM against TRPML1 and TRPML2, respectively; it shows no activity against TRPML3. Estradiol 3-methyl ether induces the disruption of cytoplasmic microtubule networks in mammalian cells, with an EC₅₀ of 9 μM. Independent of estrogen receptors, Estradiol 3-methyl ether blocks autophagy (autophagy), TFEB nuclear translocation, and inhibits the migration and invasion of triple-negative breast cancer cells by suppressing TRPML1. Estradiol 3-methyl ether is applicable for relevant research on triple-negative breast cancer .

HY-168969

AA-BR-157	PROTACs	Neurological Disease Cancer
AA-BR-157 is a metallothionein 2A (MT2A) PROTAC degrader. AA-BR-157 increases intracellular zinc levels, downregulates DIAPH3, disrupts cytoskeleton remodeling, and reduces the migration and invasion abilities of cancer cells. AA-BR-157 can be used for research on triple-negative breast cancer and glioblastoma .

HY-19634

YK-3-237 1 Publications Verification	Sirtuin	Cancer
YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells .

HY-W003396

4-Bromotetrahydropyran	Biochemical Assay Reagents Drug Intermediate	Cancer
4-Bromotetrahydropyran (4-Bromotetrahydro-2H-pyran) is an intermediate. 4-Bromotetrahydropyran can be used in the synthesis of Example 32. 4-Bromotetrahydropyran can be used in triple-negative breast cancer research .

HY-168037

PROTAC PIN1 degrader-1	PROTACs PIN1	Cancer
PROTAC PIN1 degrader-1 is a PIN1-target PROTAC degrader. PROTAC PIN1 degrader-1 TFA can be used for the research of triple-negative breast cancer, pancreatic cancer, and liver cancer .

HY-155664

GPX4-IN-6	Glutathione Peroxidase Ferroptosis	Cancer
GPX4-IN-6 (Compound C25) is a GPX4 covalent inhibitor with an IC₅₀ value of 0.13 μM. GPX4-IN-6 (Compound C25) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .

HY-168950

ANXA3 degrader 1	Annexin A	Cancer
ANXA3 degrader 1 (Compound 18a5) is a highly selective ANXA3 degrader with cancer cell inhibition activity. ANXA3 degrader 1 displays excellent inhibitory effect in a triple-negative breast cancer (TNBC) tumor xenograft model (TGI=96%) .

HY-148923

MC0704	STAT	Cancer
MC0704 is a STAT3 inhibitor with an IC₅₀ value of 2.13 μM. MC0704 induces cell apoptosis and cell cycle arrest. MC0704 shows antitumor activity in mouse breast cancer models. MC0704 can be used for the research of metastatic triple-negative breast cancer (mTNBC) .

HY-N7215

Jatrophone	β-catenin Wnt	Cancer
Jatrophone is a diterpenoid with anticancer activity isolated from Jatropha isabelli. Jatrophone interferes with the Wnt/β-catenin pathway to inhibit the proliferation and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer cells.

HY-132885

PARP/EZH2-IN-1	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-1 is a first-in-class dual PARP (IC₅₀ 6.87 nM) and EZH2 (IC₅₀ 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.

HY-161601

Ferroptosis inducer-2	Ferroptosis Reactive Oxygen Species (ROS)	Cancer
Ferroptosis inducer-2 (Compound 24) is an inducer for heme oxygenase-1 (HO-1). Ferroptosis inducer-2 exhibits anticancer activity against triple-negative breast cancer (TNBC) cells through induction of ferroptosis .

HY-Y0519R

Pyrimidine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Pyrimidine (Standard) is the analytical standard of Pyrimidine. This product is intended for research and analytical applications. Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research .

HY-117426

MO-I-500	Fat Mass and Obesity-associated Protein (FTO)	Cancer
MO-I-500 is a pharmacological of FTO inhibitor with an IC₅₀ of 8.7 μM for the inhibition of purified FTO demethylase catalyzing demethylation of an artificial small methylated substrate. MO-I-500 can be used for the research of rare panresistant triple-negative inflammatory breast cancer .

HY-175975

PROTAC Akt3 Degrader-1	PROTACs Akt	Cancer
PROTAC Akt3 Degrader-1 is a highly efficient and selective PROTAC degrader targeting Akt3. PROTAC Akt3 Degrader-1 shows weak antiproliferative activity in 36 cell lines. PROTAC Akt3 Degrader-1 can be used for the study of Triple-negative breast cancer and melanoma .

HY-149847

JH530	Ras	Cancer
JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research .

HY-119377

UPGL00004	Glutaminase	Cancer
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC₅₀=29 nM; K_d=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines .

HY-176853

Myt1-IN-6	Wee1	Cancer
Myt1-IN-6 (Compound formula (1)) is a highly selective MYT1 kinase inhibitor. Myt1-IN-6 is promising for research of RB1-deficient cancers (e.g., triple-negative breast cancer) .

HY-164064

Anticancer agent 230	ClpP	Cancer
Anticancer agent 230 (example 65) is a caseinolytic protease P (ClpP) activator with anticancer activity. Anticancer agent 230 is able to induce the degradation of mitochondrial proteins in SUM159 and MDA-MB-231 triple-negative breast cancer cells in a time-dependent manner .

HY-122703

BETi-211	Epigenetic Reader Domain	Cancer
BETi-211 is an orally active BET inhibitor (K_i: <1 nM). BETi-211 inhibits growth of triple-negative breast cancers (TNBC) cell lines with IC₅₀ < 1 μM. BETi-211 degrades BET proteins and suppress tumor growth in xenograft breast tumors .

HY-161774

ST80	CD73	Cancer
ST80 is an inhibitor for interaction of OTUD4 and CD73. ST80 decreases CD73 protein level, increases CD73 protein turnover, reduces immune evasion of tumor cells, and thus exhibits antitumor efficacy against immunosuppressive triple-negative breast cancer (TNBC) .

HY-179386

PARP1/EZH2-IN-1	PARP Histone Methyltransferase Apoptosis Pyroptosis Necroptosis Reactive Oxygen Species (ROS) PANoptosis	Cancer
PARP1/EZH2-IN-1 is a selective PARP1 and EZH2 dual inhibitor. PARP1/EZH2-IN-1 has IC₅₀s of 28 nM, 414 nM and 74 nM for PARP1, PARP2 and EZH2, respectively. PARP1/EZH2-IN-1 inhibits the proliferation and migration of TNBC cells (triple-negative breast Cancer cells). PARP1/EZH2-IN-1 induces PANoptosis (Apoptosis, Pyroptosis and Necroptosis), increases the level of reactive oxygen species (ROS), and activates related inflammatory pathways. PARP1/EZH2-IN-1 can be used in triple-negative breast cancer research .

HY-179180

PD-1/PD-L1-IN-59	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-59 (Compound MZ51) is a PD-1/PD-L1 inhibitor with an IC₅₀ of 183 nM. PD-1/PD-L1-IN-59 can be used for the study of triple-negative breast cancer (TNBC) .

HY-142908

Maximiscin	Endogenous Metabolite	Cancer
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-125465

SLLN-15	Autophagy	Cancer
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) .

HY-N8098

Pulchinenoside E2	STAT Autophagy JAK	Cancer
Pulchinenoside E2 is a triterpenoid saponin. Pulchinenoside E2 inhibits the phosphorylation of STAT3 and JAK2, blocks the nuclear translocation and transcriptional activity of STAT3, and suppresses STAT3-dependent mitochondrial oxidative phosphorylation. Pulchinenoside E2 inhibits invasion, migration and autophagy of triple-negative breast cancer cells. Pulchinenoside E2 can be used in research related to triple-negative breast cancer .

HY-132883

EGFR/CSC-IN-1	EGFR	Cancer
EGFR/CSC-IN-1 is a potential EGFR (IC₅₀ 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer research.

HY-163381

Antiproliferative agent-48	Drug Intermediate	Cancer
Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .

HY-161831

Antitumor agent-175	Reactive Oxygen Species (ROS)	Cancer
Antitumor agent-175 (Compound Ru2) is an antitumor agent with photocytotoxicity, demonstrating selective antitumor effects against triple-negative breast cancer (TNBC) cells .

HY-150757

Autophagy-IN-2	Autophagy Apoptosis	Cancer
Autophagy-IN-2 (Compound 7h) is an autophagic flux inhibitor. Autophagy-IN-2 induces cancer cell apoptosis and can be used for triple-negative breast cancer research .

HY-178274

SKLB06329	Histone Methyltransferase Apoptosis	Cancer
SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC₅₀ = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs). SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research .

HY-149259

FAK-IN-9	FAK	Cancer
FAK-IN-9 (Compound 8f) is a potent and orally active FAK inhibitor with an IC₅₀ of 27.44 nM. FAK-IN-9 induces triple-negative breast cancer (TNBC) cell apoptosis .

HY-174836

ZINC000081009201	PARP	Cancer
ZINC000081009201 is a potent poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with an IC₅₀ value of 1.4767 μM. ZINC000081009201 is promising for research of triple-negative breast cancer (TNBC) .

HY-N0770R

Isoliensinine (Standard)	Reference Standards Apoptosis	Inflammation/Immunology Cancer
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells .

HY-163275

MDM2-IN-24	MDM-2/p53 Apoptosis	Cancer
MDM2-IN-24 (compound A3f) exhibits MDM2-inhibiting and MDMX-activating properties in triple-negative breast cancer (TNBC) cells, with apoptotic and anti-proliferative activities .

HY-139376

FGFR1 inhibitor-2	FGFR	Cancer
FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC₅₀ is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library

3,181 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 3,181 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-164789

Sacituzumab tirumotecan

SKB264; MK-2870

Fluorescent Dye

Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC₅₀ of 2.787 ng/ml, TROP2 K_a of 0.3083 nM, and topoisomerase I IC₅₀ of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .

HY-169130

Lyso BD-1	Fluorescent Dye
Lyso BD-1, preferentially colocalized in lysosomes and lipid droplets, displays excellent photocytotoxicity (5.57 μM) on triple negative breast cancer cells under white light. Lyso BD-1 displays emission band at 560nm .

HY-D3311

M1219

Fluorescent Dye

M1219 is a GSH/ATP dual near-infrared activated fluorescent probe that enables independent real-time monitoring of dynamic changes in intracellular GSH and ATP without spectral crosstalk (GSH: Ex=640 nm, Em=740~800 nm; ATP: Ex=594 nm/610 nm, Em=650~700 nm). M1219 not only visualizes the metabolic regulatory mechanism of TNBC under single/dual-target inhibition of SLC7A11/GLUT1 and accurately evaluates its in vivo efficacy, but also achieves precise localization of the TNBC tumor invasion boundary. M1219 can be used for the research of triple-negative breast cancer .

Cat. No.	Product Name	Type

HY-NP163A

Wheat germ agglutinin-AF488

WGA-AF488

Biochemical Assay Reagents

Wheat germ agglutinin-AF488 (WGA-AF488) is a cell membrane-specific staining agent prepared by conjugating wheat germ agglutinin with the Alexa Fluor 488 (HY-D1304) fluorescent dye, and it binds to cell surface glycoproteins with high affinity. Wheat germ agglutinin-AF488 is applied in fluorescence microscopy and confocal imaging techniques, and it can clearly label the membrane structures of various cells including breast cancer cells, enabling high-resolution visual observation. Wheat germ agglutinin-AF488 is used in studies of breast cancer and triple-negative breast cancer to observe cell morphology and membrane dynamic changes .

HY-W441002

DSPE-succinic acid	Biochemical Assay Reagents
DSPE-succinic acid is a derivative of Succinic acid (HY-N0420) and an intermediate of DSPE-Doxorubicin. DSPE-succinic acid can be used to synthesize DSPE-Doxorubicin via EDC/NHS activation. DSPE-succinic acid is applicable to the research of triple-negative breast cancer .

HY-W003396

4-Bromotetrahydropyran	Biochemical Assay Reagents
4-Bromotetrahydropyran (4-Bromotetrahydro-2H-pyran) is an intermediate. 4-Bromotetrahydropyran can be used in the synthesis of Example 32. 4-Bromotetrahydropyran can be used in triple-negative breast cancer research .

HY-W440913

DSPE-PEG5000-Cy5

Biochemical Assay Reagents

DSPE-PEG-Cy5, MW 5000 is a fluorescently labeled PEGylated phospholipid with a molecular weight of 5000 Da. After intravenous injection, DSPE-PEG-Cy5, MW 5000 shows only extremely low fluorescence accumulation at tumor sites in orthotopic tumor-bearing mice, and can be used as a negative control for evaluating tumor accumulation of nanoparticles. DSPE-PEG-Cy5, MW 5000 can serve as a fluorescent marker to prepare Cy5-labeled NPs-DPPA and NPs-DPPA (C3F8) for pharmacokinetic and biodistribution studies in mice. DSPE-PEG-Cy5, MW 5000 is widely applicable to research in fields related to triple-negative breast cancer, hepatocellular carcinoma and so on .

Cat. No.	Product Name	Target	Research Area

HY-P11051

GE11, Cys Conjugated	Biochemical Assay Reagents	Cancer
GE11, Cys Conjugated is a peptide conjugate. GE11, Cys Conjugated consists of GE11 (HY-P10128) conjugated to a GGGGC sequence. GE11, Cys Conjugated can be used to synthesize stimulus-responsive peptide nanomaterials (SRPNs) for photoacoustic imaging and cancer research, such as studies on triple-negative breast cancer (TNBC) .

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

HY-P10853

Bacilotetrin C analogue	Autophagy	Cancer
Bacilotetrin C analogue is cytotoxic to triple-negative breast cancer cell line MDA-MB-231 with an IC₅₀ of 0.48 μM. Bacilotetrin C analogue can induce tumor cell autophagy and has anti-tumor activity .

HY-P11280A

PRAME peptide (425-433) acetate	Melanocortin Receptor	Cancer
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative* breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .

HY-183488

R9-caPep RRRRRRRRRCCLGIPEQEY	Apoptosis PARP	Cancer
R9-caPep (RRRRRRRRRCCLGIPEQEY) is a cell-penetrating peptide derived from proliferating cell nuclear antigen (PCNA). R9-caPep selectively blocks the interactions between PCNA and FEN1, as well as between PCNA and LIGI, while preserving the binding of POLD3 to PCNA. R9-caPep interferes with DNA synthesis and homologous recombination-mediated double-strand DNA break repair, inducing S-phase arrest, DNA damage accumulation, and apoptosis. R9-caPep inhibits the growth of tumor volume and weight of neuroblastoma in nude mice . R9-caPep can be used in research related to neuroblastoma and triple-negative breast cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99045

Sacituzumab 4 Publications Verification HRS7; hRS7	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-P99843

Datopotamab 1 Publications Verification	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P990211

Anti-Mouse IL-6R Antibody (15A7)	Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse IL-6R Antibody (15A7) is a rat-derived anti-mouse IL-6R IgG2b κ type antibody inhibitor. Anti-Mouse IL-6R Antibody (15A7) blocks IL-6 binding to IL-6Rα and inhibits both IL-6 classic and trans-signaling. Anti-Mouse IL-6R Antibody (15A7) can be used for the researches of cancer and inflammation, such as triple-negative breast cancer .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HY-P99045A

Sacituzumab (powder)	ADC Antibody TROP2	Cancer
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-P990717

Brenetafusp IMC-F106C	CD3	Cancer
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3 ⁺ T cells to kill PRAME ⁺ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P99682

Ladiratuzumab hLIV22	ADC Antibody	Cancer
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .

HY-P99007

Aprutumab BAY 1179470	FGFR	Cancer
Aprutumab (BAY 1179470) is a fully human fibroblast growth factor receptor 2 (FGFR2)-specific monoclonal antibody . Aprutumab induces FGFR2 endocytosis and degradation in cancer cells expressing FGFR2. Aprutumab serves as the targeted monoclonal antibody component of the antibody-drug conjugate BAY 1187982 (HY-141600) and mediates the endocytosis of the antibody-drug conjugate into FGFR2-positive cells. Aprutumab can be used for the research of FGFR2-positive solid tumors, including studies on gastric cancer and triple-negative breast cancer .

HY-P991742

LY4101174 Antibody 15A7.5; ETx-22 Antibody	ADC Antibody	Cancer
LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

HY-P991292

AB-3A4	ADC Antibody	Cancer
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P991572

MM-151	EGFR	Cancer
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .

HY-P991356

FAZ-053 LAE-005	PD-1/PD-L1	Cancer
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .

HY-P992391

IPH4301 IPH43	C-type Lectin-like Receptors (CTLRs) Apoptosis	Cancer
IPH4301 is a monoclonal antibody targeting MICA/B, with dual activities of cytotoxicity and immunoregulation . IPH4301 blocks the interaction between MICA/B and NKG2D, inhibits their hydrolysis into soluble sMICA/B, and mediates antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against tumor cells expressing MICA/MICB. IPH4301 restores the expression and function of NKG2D on primary NK cells and T cells, reverses the immunosuppression induced by M2 macrophages, and enhances NK cell-mediated tumor cell apoptosis. IPH4301 can be used in research related to cancer and triple-negative breast cancer .

HY-P992488

ZV05 ZV0501 Antibody	Transmembrane Glycoprotein ADC Antibody	Cancer
ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC₅₀ of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer .

HY-P992341

D8P1C1	MMP	Cancer
D8P1C1 is a high-affinity ADAM17 inhibitor (with a K_d of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. ⁸⁹Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .

HY-P991864

Annexuzlimab MDX-124	Formyl Peptide Receptor (FPR)	Cancer
Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma .

HY-P992441

PHST001	Transmembrane Glycoprotein	Cancer
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0770

Isoliensinine 4 Publications Verification	Alkaloids Monophenols Classification of Application Fields Phenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Nymphaeaceae Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells .

HY-N0554

Escin IA 1 Publications Verification	Infection Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Hippocastanaceae Aesculus hippocastanum Plants Disease Research Fields Source Classification Cancer	HIV Protease Monoamine Oxidase
Escin IA is an oral LOXL2 inhibitor and EMT inhibitor, with selectivity for LOXL2-expressing cells. Escin IA suppresses invasion, migration, and metastasis of breast cancer cells, and acts as the primary anti-TNBC metastasis constituent of Aesculus chinensis Bunge fruit saponin fraction. Escin IA can be used for the research of triple-negative breast cancer, acute inflammation, and ethanol-induced gastric mucosal lesions .

HY-N0168A

(Rac)-Hesperetin	Structural Classification Flavonoids other families Flavonones Phenols Polyphenols Plants Source Classification	TGF-beta/Smad NF-κB
(Rac)-Hesperetin is the racemate of Hesperetin (HY-N0168), an orally active multi-target inhibitor. (Rac)-Hesperetin exhibits significant anti-tumor and anti-inflammatory activities by blocking the TGF-β1-mediated Fyn/RhoA signaling axis and the TLR4-MyD88-NF-κB inflammatory pathway. (Rac)-Hesperetin inhibits the formation of actin stress fibers and the migration and invasion of cancer cells, and is suitable for triple-negative breast cancer research. In inflammation models, (Rac)-Hesperetin effectively alleviates lung injury by reducing the release of pro-inflammatory mediators and regulating the activity of oxidative stress enzymes, and is suitable for acute lung injury research. (Rac)-Hesperetin also interferes with the entry and early replication processes of channel catfish virus, inhibits viral gene expression and progeny virus production, thereby protecting cells from virus-induced cytopathic effects .

HY-N0331

Ziyuglycoside I 1 Publications Verification	Triterpenes Classification of Application Fields Sanguisorba officinalis Linn. Terpenoids Rosaceae Plants Disease Research Fields Source Classification Cancer	MDM-2/p53 Apoptosis
Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics . Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential agent candidate for treating triple-negative breast cancer (TNBC) .

HY-N0858

Gomisin G 2 Publications Verification	Infection Classification of Application Fields Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields Source Classification	HIV
Gomisin G is a lignin from S. chinesis with anti-HIV (EC₅₀ = 0.006 μg/mL), anti-liver cancer and anti-inflammatory activities. Gomisin G has an AKT-cyclin D1 dependent mechanism against triple-negative breast cancer (TNBC) cells through suppressing phosphorylation rather than inducing apoptosis. Gomisin G can inhibit AKT phosphorylation. Gomisin G can cause cell cycle arrest in the G1 phase. Gomisin G can be studied in research for diseases such as HIV, breast and liver cancers .

HY-Y0519

Pyrimidine	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research .

HY-N7694

Isotoosendanin 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Melia toosendan Sieb. et Zucc. Plants Meliaceae Inflammation/Immunology Disease Research Fields Source Classification	TGF-β Receptor JAK STAT Apoptosis
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-N6007

Chrysosplenol D 1 Publications Verification	Infection Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities .

HY-135319

Strictinin	Structural Classification Phenols Polyphenols Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Bacterial Antibiotic ERK JNK NF-κB ROR Apoptosis Caspase GSK-3 Akt PI3K
Strictinin is an orally active phenolic compound. Strictinin reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in hepatocytes treated with Xanthine (HY-W017389). Strictinin decreases elevated serum uric acid levels and enhanced xanthine oxidase activity in mice treated with potassium oxonate. Strictinin acts as a ROR1 inhibitor and exhibits anticancer activity against highly aggressive non-androgen-dependent prostate cancer. Strictinin induces cancer cell apoptosis (apoptosis), arrests cell cycle, and inhibits cancer cell migration, invasion, and epithelial-mesenchymal transition. Strictinin modulates gut microbiota, inhibits bacterial growth and biofilm formation, accelerates small intestinal transit, and blocks viral entry and replication. Strictinin can be used in research related to hyperuricemia, androgen receptor-negative non-androgen-dependent prostate cancer, triple-negative breast cancer, bacterial infections, constipation, coronavirus infections, dental caries, and infections caused by influenza A, influenza B, and human parainfluenza virus type 1 .

HY-118618

Eucannabinolide Hiyodorilactone A; Schkuhrin I	Terpenoids Sesquiterpenes Plants Compositae Guilandina minax (Hance) G. P. Lewis Source Classification	STAT
Eucannabinolide is a STAT3 inhibitor. Eucannabinolide suppresses STAT3 activation at tyrosine 705, inhibiteds its translocation to nucleus, and decreases its DNA binding capacity. Eucannabinolide can be used for triple negative breast cancer (TNBC) diseases research .

HY-N7215

Jatrophone	Microorganisms Terpenoids Diterpenoids Source Classification	β-catenin Wnt
Jatrophone is a diterpenoid with anticancer activity isolated from Jatropha isabelli. Jatrophone interferes with the Wnt/β-catenin pathway to inhibit the proliferation and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer cells.

HY-Y0519R

Pyrimidine (Standard)	Structural Classification Natural Products Microorganisms Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Pyrimidine (Standard) is the analytical standard of Pyrimidine. This product is intended for research and analytical applications. Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research .

HY-142908

Maximiscin	Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-N8098

Pulchinenoside E2	Triterpenes Structural Classification Classification of Application Fields Terpenoids Ranunculaceae Plants Disease Research Fields Pulsatilla chinensis (Bunge) Regel Source Classification Cancer	STAT Autophagy JAK
Pulchinenoside E2 is a triterpenoid saponin. Pulchinenoside E2 inhibits the phosphorylation of STAT3 and JAK2, blocks the nuclear translocation and transcriptional activity of STAT3, and suppresses STAT3-dependent mitochondrial oxidative phosphorylation. Pulchinenoside E2 inhibits invasion, migration and autophagy of triple-negative breast cancer cells. Pulchinenoside E2 can be used in research related to triple-negative breast cancer .

HY-N0770R

Isoliensinine (Standard)	Alkaloids Structural Classification Monophenols Phenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Nymphaeaceae Source Classification	Reference Standards Apoptosis
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells .

HY-N0331R

Ziyuglycoside I (Standard)	Triterpenes Structural Classification Sanguisorba officinalis Linn. Terpenoids Rosaceae Plants Source Classification	Reference Standards MDM-2/p53 Apoptosis
Ziyuglycoside I (Standard) is the analytical standard of Ziyuglycoside I. This product is intended for research and analytical applications. Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics . Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential agent candidate for treating triple-negative breast cancer (TNBC) .

HY-N0858R

Gomisin G (Standard)	Structural Classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Source Classification	Reference Standards HIV
Gomisin G (Standard) is the analytical standard of Gomisin G. This product is intended for research and analytical applications. Gomisin G is a lignin from S. chinesis with anti-HIV (EC₅₀ = 0.006 μg/mL), anti-liver cancer and anti-inflammatory activities. Gomisin G has an AKT-cyclin D1 dependent mechanism against triple-negative breast cancer (TNBC) cells through suppressing phosphorylation rather than inducing apoptosis. Gomisin G can inhibit AKT phosphorylation. Gomisin G can cause cell cycle arrest in the G1 phase. Gomisin G can be studied in research for diseases such as HIV, breast and liver cancers .

HY-N0168AR

(Rac)-Hesperetin (Standard)	Structural Classification Flavonoids other families Flavonones Phenols Polyphenols Plants Source Classification	Reference Standards NF-κB TGF-beta/Smad
(Rac)-Hesperetin (Standard) is the analytical standard of (Rac)-Hesperetin. This product is intended for research and analytical applications. (Rac)-Hesperetin is the racemate of Hesperetin (HY-N0168), an orally active multi-target inhibitor. (Rac)-Hesperetin exhibits significant anti-tumor and anti-inflammatory activities by blocking the TGF-β1-mediated Fyn/RhoA signaling axis and the TLR4-MyD88-NF-κB inflammatory pathway. (Rac)-Hesperetin inhibits the formation of actin stress fibers and the migration and invasion of cancer cells, and is suitable for triple-negative breast cancer research. In inflammation models, (Rac)-Hesperetin effectively alleviates lung injury by reducing the release of pro-inflammatory mediators and regulating the activity of oxidative stress enzymes, and is suitable for acute lung injury research. (Rac)-Hesperetin also interferes with the entry and early replication processes of channel catfish virus, inhibits viral gene expression and progeny virus production, thereby protecting cells from virus-induced cytopathic effects .

HY-N18190

N-Desmethyldauricine	Structural Classification Alkaloids Plants Isoquinoline Alkaloids Menispermaceae Menispermum dauricum Source Classification	NF-κB Apoptosis
N-Desmethyldauricine is a NF-κB p65 inhibitor and apoptosis inducer. N-Desmethyldauricine reduces the protein expression level of p65, induces apoptosis, arrests the cell cycle at the G0/G1 phase, attenuates intercellular adhesion, and inhibits the growth of 3D spheroids of triple-negative breast cancer. N-Desmethyldauricine can be used in studies related to triple-negative breast cancer .

HY-N17312

(-)-Mornaphthoate B	Structural Classification Lignans Rubiaceae Phenylpropanoids Plants Morinda officinalis How Source Classification	Drug Derivative
(-)-Mornaphthoate B is a Methyl 2-naphthoate derivative. (-)-Mornaphthoate B can be isolated from the roots of Morinda officinalis var. officinalis. (-)-Mornaphthoate B exhibits no activity against Acetylcholinesterase and Butyrylcholinesterase. (-)-Mornaphthoate B can be used in the research of non-small cell lung cancer and triple-negative breast cancer .

HY-N17319A

(+)-Mornaphthoate D	Structural Classification Morinda officinalis var. officinalis Rubiaceae Phenols Polyphenols Plants Morinda officinalis How Source Classification
(+)-Mornaphthoate D is a Methyl 2-naphthoate derivative. (+)-Mornaphthoate D can be isolated from the roots of Morinda officinalis var. officinalis. (+)-Mornaphthoate D exhibits no activity against Acetylcholinesterase and Butyrylcholinesterase. (+)-Mornaphthoate D can be used in the research of non-small cell lung cancer and triple-negative breast cancer .

HY-N17556

(+)-Mornaphthoate B	Structural Classification Monophenols Rubiaceae Phenols Plants Morinda officinalis How Source Classification	Drug Derivative
(+)-Mornaphthoate B is a Methyl 2-naphthoate derivative. (+)-Mornaphthoate B can be isolated from the roots of Morinda officinalis var. officinalis. (+)-Mornaphthoate B exhibits no activity against Acetylcholinesterase and Butyrylcholinesterase. (+)-Mornaphthoate B can be used in the research of non-small cell lung cancer and triple-negative breast cancer .

HY-N17319

(-)-Mornaphthoate D	Structural Classification Morinda officinalis var. officinalis Rubiaceae Phenols Polyphenols Plants Morinda officinalis How Source Classification	Drug Derivative
(-)-Mornaphthoate D is a Methyl 2-naphthoate derivative. (-)-Mornaphthoate D can be isolated from the roots of Morinda officinalis var. officinalis. (-)-Mornaphthoate D exhibits no activity against Acetylcholinesterase and Butyrylcholinesterase. (-)-Mornaphthoate D can be used in the research of non-small cell lung cancer and triple-negative breast cancer .

Cat. No.	Product Name	Chemical Structure

HY-N0168AS1

(Rac)-Hesperetin-13C,d3

(Rac)-Hesperetin- ¹³C,d₃ is the ¹³C- and deuterium labeled (Rac)-Hesperetin. (Rac)-Hesperetin is the racemate of Hesperetin (HY-N0168), an orally active multi-target inhibitor. (Rac)-Hesperetin exhibits significant anti-tumor and anti-inflammatory activities by blocking the TGF-β1-mediated Fyn/RhoA signaling axis and the TLR4-MyD88-NF-κB inflammatory pathway. (Rac)-Hesperetin inhibits the formation of actin stress fibers and the migration and invasion of cancer cells, and is suitable for triple-negative breast cancer research. In inflammation models, (Rac)-Hesperetin effectively alleviates lung injury by reducing the release of pro-inflammatory mediators and regulating the activity of oxidative stress enzymes, and is suitable for acute lung injury research. (Rac)-Hesperetin also interferes with the entry and early replication processes of channel catfish virus, inhibits viral gene expression and progeny virus production, thereby protecting cells from virus-induced cytopathic effects .

HY-N0168AS

(Rac)-Hesperetin-d3

(Rac)-Hesperetin-d₃ is the deuterium labeled (Rac)-Hesperetin. (Rac)-Hesperetin is the racemate of Hesperetin (HY-N0168), an orally active multi-target inhibitor. (Rac)-Hesperetin exhibits significant anti-tumor and anti-inflammatory activities by blocking the TGF-β1-mediated Fyn/RhoA signaling axis and the TLR4-MyD88-NF-κB inflammatory pathway. (Rac)-Hesperetin inhibits the formation of actin stress fibers and the migration and invasion of cancer cells, and is suitable for triple-negative breast cancer research. In inflammation models, (Rac)-Hesperetin effectively alleviates lung injury by reducing the release of pro-inflammatory mediators and regulating the activity of oxidative stress enzymes, and is suitable for acute lung injury research. (Rac)-Hesperetin also interferes with the entry and early replication processes of channel catfish virus, inhibits viral gene expression and progeny virus production, thereby protecting cells from virus-induced cytopathic effects .

Cat. No.	Product Name		Classification

HY-162874

diABZI-V/C-DBCO		DBCO
diABZI-V/C-DBCO is a STING agonist with an EC₅₀ of 1.47 nM. diABZI-V/C-DBCO activates the STING pathway, induces the production of IFN-I, and stimulates the secretion of IFN-β. diABZI-V/C-DBCO serves as a substrate for cathepsin B, and releases active diABZI-amine via cathepsin B-mediated cleavage. In an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO increases serum IFN-β levels and the frequency of granzyme B ⁺ CD8 ⁺ T cells. diABZI-V/C-DBCO is applicable to research related to triple-negative breast cancer .

HY-135699

TD52 2 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-178164

HBS-101		Alkynes
HBS-101 is a selectively, orally active, brain-penetrant, Midkine (MDK) inhibitor (K_D = 38.4 nM). HBS-101 significantly reduces cell viability, clonogenic survival, and invasiveness and increases apoptosis. HBS-101 involves suppression of the Akt/mTOR, STAT3, and NF-κB pathways. HBS-101 can be used for the study of Triple-negative breast cancer (TNBC) .

HY-135699A

TD52 dihydrochloride 2 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-132913

Cyclopropenone probe 1		Alkynes
Cyclopropenone probe 1 can specifically and efficiently modify a triple-negative breast cancer driver, glutathione S-transferase pi-1 (GSTP1), by covalently binding at the catalytic active site. Cyclopropenone probe 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

HY-181483

CDK6-IN-2		Alkynes
CDK6-IN-2 is a CDK6 covalent inhibitor with an IC₅₀ of 0.013 μM. CDK6-IN-2 inhibits the proliferation and migration of triple-negative breast cancer cells, and induces cell cycle arrest and apoptosis. CDK6-IN-2 induces ROS accumulation and mitochondrial damage through cellular metabolic reprogramming. CDK6-IN-2 exhibits anti-tumor activity and can be used for the research of triple-negative breast cancer .

Cat. No.	Product Name		Classification

HY-W011725

N-6-Methyl-2-deoxyadenosine m6dA		Nucleoside Analogs Adenosine
N-6-Methyl-2-deoxyadenosine (m6dA) is an adenine nucleoside analogue. N-6-Methyl-2-deoxyadenosine targets nuclear processes and DNA replication machineries including WER, SATB1, TFAM, Jumu, SSBP1, DNA polymerase η and phage polymerase Gp90 exo ⁻. N-6-Methyl-2-deoxyadenosine acts as a multifunctional epigenetic regulator that modulates transcription, DNA damage response, cell cycle, transposon silencing, stress adaptation, epigenetic crosstalk, and nucleosome organization in both prokaryotes and eukaryotes. N-6-Methyl-2-deoxyadenosine regulates mitochondrial epigenetic inheritance and is required for fear extinction memory in mice. N-6-Methyl-2-deoxyadenosine exhibits dysregulated levels in cancers. N-6-Methyl-2-deoxyadenosine can be used for the research of glioblastoma, triple negative breast cancer, and conditioned fear (fear extinction impairment) .

HY-W441002

DSPE-succinic acid		Phospholipids
DSPE-succinic acid is a derivative of Succinic acid (HY-N0420) and an intermediate of DSPE-Doxorubicin. DSPE-succinic acid can be used to synthesize DSPE-Doxorubicin via EDC/NHS activation. DSPE-succinic acid is applicable to the research of triple-negative breast cancer .

HY-W440913

DSPE-PEG5000-Cy5		Pegylated Lipids Fluorescent Lipids
DSPE-PEG-Cy5, MW 5000 is a fluorescently labeled PEGylated phospholipid with a molecular weight of 5000 Da. After intravenous injection, DSPE-PEG-Cy5, MW 5000 shows only extremely low fluorescence accumulation at tumor sites in orthotopic tumor-bearing mice, and can be used as a negative control for evaluating tumor accumulation of nanoparticles. DSPE-PEG-Cy5, MW 5000 can serve as a fluorescent marker to prepare Cy5-labeled NPs-DPPA and NPs-DPPA (C3F8) for pharmacokinetic and biodistribution studies in mice. DSPE-PEG-Cy5, MW 5000 is widely applicable to research in fields related to triple-negative breast cancer, hepatocellular carcinoma and so on .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Triple+Negative

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products